EUCTR2005-004294-21-IT进行中（未招募）不适用
phase II study of the trifunctional anti-her-2/neu x anti-cd3 antibodyertumaxomab for hormone therapy refractory patients with her-2/neu 1 or 2 expressing advanced or metastatic breast cancer - ND
FRESENIUS BIOTECH GMBH0 个研究点目标入组 40 人开始时间: 2006年6月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •a Female gender, and if of child-bearing potential must have a negative pregnancy test result within 2 days before enrolment and must agree to practice effective birth control during the study. b Aged 18 years and older. c Histologically or cytologically confirmed invasive breast cancer with stage IIIb or IV disease with documented progression. d Measurable disease according to RECIST. e Histologically documented advanced primary breast cancer or biopsy of metastatic site demonstrating HER-2/neu expression HER-2/neu 1 or 2 determined by immunohistochemistry IHC . HER-2/neu 2 patients must have a negative FISH test. If an IHC test other than the Dako HercepTest has been performed, then a confirmatory Dako HercepTest has to be performed at the central laboratory. The results of the IHC tests other than the Dako HercepTest can be accepted for inclusion, but the results from these tests have to be confirmed by the Dako HercepTest afterwards. f Hormone receptor status ERs positive and/or PRs positive. g No prior treatment with mouse or rat antibodies. h Life expectancy of at least six months if the life expectancy of a patient is unspecified she will be allowed to enter the study . i An Eastern Cooperative Oncology Group ECOG performance score of 1. j Patients must have had disease progression after hormonal therapy including at least one aromatase inhibitor. k Adequate hematological, liver and kidney function refer to exclusion criterion i
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a Pregnant or lactating women. b Life-threatening visceral disease. c Known brain or central nervous system metastases. d Symptomatic pleural effusions. e Symptomatic pericardial effusions. f History of relevant cardiovascular disease Left ventricular ejection fraction LVEF below normal institutional ranges as measured by echocardiogram or MUGA scan Uncontrolled or symptomatic congestive heart failure New York Heart Association NYHA Classification 2 Myocardial infarction within the past two years Uncontrolled or symptomatic cardiac arrhythmias g Severe dyspnea. h Pulmonary dysfunction or require continuous supportive oxygen inhalation. i Symptoms or signs including laboratory tests of relevant concomitant hematological, hepatic, renal disease, in particular Thrombocytes 100 x 109/l Hemoglobin Hb 10 g/dl Neutrophil count 1500/mm3 1.5 x 109/l White blood cells WBC 3 x 109/l Serum glutamic oxaloacetic transaminase SGOT and serum glutamic pyruvate transaminase SGPT 2.5 x upper limit of normal ULN Serum bilirubin 2 x ULN Creatinine 1.5 x ULN or clearance 60 ml/min j Patients whose only site of metastatic involvement is bone metastases. With the exception of those with a measurable soft tissue component of the bone lesion seen with imaging that does not require palliative radiation intervention and/or the patient has a lytic bone lesion 1 cm measured with radiography that can be followed for evidence of re-calcification. k Other concurrent uncontrolled co-morbid illness. l Other concurrent malignancy, except treated basal cell or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix. m Patients with documented autoimmune diseases such as lupus are excluded from participation in the study unless a waiver is granted by the responsible medical monitor. n Human immunodeficiency virus, hepatitis B or hepatitis C positive status. o Any prior or concurrent chemotherapy regimen for advanced or metastatic disease. p Prior neo-adjuvant or adjuvant chemotherapy was stopped less than six months before study entry. q Any concurrent hormone therapy. Hormone therapy must be stopped at latest at the screening visit. r Radiotherapy within 4 weeks before study entry. s Any concurrent immune therapy. t Any concurrent corticosteroid therapy. u Any prior investigational therapy for advanced or metastatic disease. v Any regularly used medication for a health condition or comorbidity that might result in undue risk to the patient. w Unable or unwilling to comply fully with the protocol.
研究者
相似试验
进行中（未招募）
不适用
Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancerHormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+)EUCTR2005-004294-21-BEFresenius Biotech GmbH40
进行中（未招募）
不适用
Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancerEUCTR2005-004294-21-ATFresenius Biotech GmbH40
招募中
不适用
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer.breast cancerJPRN-UMIN000038644Hoshi University Division of Applied Pharmaceutical89
进行中（未招募）
不适用
Estudio de fase II del anticuerpo trifuncional anti-HER-2/neu x anti-CD3 ertumaxomab en pacientes con cáncer de mama avanzado o metastásico resistente al tratamiento hormonal que expresa HER2/neu 1+ o 2Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancerCáncer de mama avanzado o metastásico (estadio IIIb o IV) que se sepa que expresa HER-2/neu (1+ o 2+) y que es resistente a hormonoterapiaHormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+)EUCTR2005-004294-21-ESFresenius Biotech GmbH40
已完成
2 期
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin.on-surgical malignant esophagus tumors.Esophageal NeoplasmsCarcinomaGastrointestinal NeoplasmsBiliary Tract NeoplasmsDigestive System NeoplasmsEsophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesNeoplasms, Glandular and EpithelialRPCEC00000014Center of Molecular Immunology(CIM)68